Released last week by the U.S. Department of Health and Human Services (HHS) Office of the Inspector General (OIG), a new federal toolkit aims to help health-care stakeholders analyze their telehealth claims data to assess program integrity risks.
The toolkit is based on the methodology developed for a report published September 2022 that assessed providers who billed Medicare for telehealth services. The previous report determined that of 742,000 providers billing for telehealth, 1,714 providers engaged in billing that posed a high risk to Medicare.
This toolkit is designed to help public and private sector partners, including Medicare Advantage plan sponsors, private health plans, and State Medicaid Fraud Control Units, assess the integrity risks associated with telehealth-related billing.
Related Posts
American Telemedicine Association Publishes New Health Data Privacy Principles
Amid rising concerns about data privacy within the telehealth arena, the American Telemedicine Association (ATA) released a set of principles to ensure patient data is protected during telehealth utilization. The ATA’s Health Data Privacy Principles include six components: The ATA states that a federal policy would offer much-needed consistency in data privacy practices for telehealth providers…
New Federal Resource on Protecting the Privacy and Security of Consumer’s Health Information
The Federal Trade Commission (FTC) and the Department of Health and Human Services (HHS) recently released a joint publication that provides guidance and practical advice to all entities that collect, share, or use consumer information. Collecting, Using, or Sharing Consumer Health Information gathers all of the various legal obligations in one place and focuses on…
Congressional White Paper Recommends a Sector-by-Sector Approach to Regulating Artificial Intelligence
Senate Health Committee ranking Republican Bill Cassidy (LA) released a white paper on September 6 suggesting Congress refrain from crafting a government-wide approach to overseeing artificial intelligence and only step in when an agency’s oversight falls short, such as filling gaps in U.S. Food and Drug Administration’s (FDA) ability to regulate artificial intelligence (AI) as…